23.45
price up icon1.16%   0.27
after-market After Hours: 23.45
loading
Pfizer Inc stock is traded at $23.45, with a volume of 26.07M. It is up +1.16% in the last 24 hours and down -1.43% over the past month. Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$23.18
Open:
$23.325
24h Volume:
26.07M
Relative Volume:
0.53
Market Cap:
$133.32B
Revenue:
$62.46B
Net Income/Loss:
$7.88B
P/E Ratio:
16.99
EPS:
1.38
Net Cash Flow:
$11.22B
1W Performance:
+1.78%
1M Performance:
-1.43%
6M Performance:
-10.53%
1Y Performance:
-15.71%
1-Day Range:
Value
$23.16
$23.45
1-Week Range:
Value
$22.88
$23.66
52-Week Range:
Value
$20.91
$31.54

Pfizer Inc Stock (PFE) Company Profile

Name
Name
Pfizer Inc
Name
Phone
(212) 733-2323
Name
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Name
Employee
81,000
Name
Twitter
@Pfizer
Name
Next Earnings Date
2025-02-04
Name
Latest SEC Filings
Name
PFE's Discussions on Twitter

Compare PFE with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
PFE
Pfizer Inc
23.45 130.99B 62.46B 7.88B 11.22B 1.38
Drug Manufacturers - General icon
LLY
Lilly Eli Co
722.57 650.81B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
153.58 368.56B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
ABBV
Abbvie Inc
185.62 321.13B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
112.58 222.75B 53.22B 12.86B 14.85B 6.39
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
69.46 303.04B 43.59B 15.04B 10.74B 3.3766

Pfizer Inc Stock (PFE) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-22-25 Initiated Cantor Fitzgerald Neutral
Dec-10-24 Resumed BofA Securities Neutral
Nov-15-24 Initiated Wolfe Research Underperform
Oct-25-24 Resumed Citigroup Neutral
Oct-17-24 Initiated Bernstein Mkt Perform
Aug-07-24 Upgrade Daiwa Securities Neutral → Outperform
Mar-22-24 Downgrade Argus Buy → Hold
Feb-23-24 Initiated Guggenheim Buy
Jan-04-24 Downgrade TD Cowen Outperform → Market Perform
Oct-20-23 Resumed UBS Neutral
Oct-16-23 Upgrade Jefferies Hold → Buy
Jul-17-23 Reiterated JP Morgan Neutral
Jul-14-23 Initiated HSBC Securities Buy
Jun-29-23 Downgrade Credit Suisse Outperform → Neutral
May-11-23 Downgrade Daiwa Securities Outperform → Neutral
Mar-06-23 Initiated Jefferies Hold
Feb-07-23 Upgrade Daiwa Securities Neutral → Outperform
Jan-26-23 Downgrade UBS Buy → Neutral
Jan-17-23 Downgrade Wells Fargo Overweight → Equal Weight
Jan-04-23 Downgrade BofA Securities Buy → Neutral
Dec-13-22 Upgrade Goldman Neutral → Buy
Nov-18-22 Initiated Credit Suisse Outperform
May-23-22 Initiated SVB Leerink Mkt Perform
Apr-06-22 Resumed Morgan Stanley Equal-Weight
Jan-05-22 Upgrade BofA Securities Neutral → Buy
Jan-03-22 Reiterated Bernstein Mkt Perform
Dec-20-21 Reiterated Cowen Outperform
Dec-17-21 Initiated Goldman Neutral
Dec-13-21 Upgrade UBS Neutral → Buy
Dec-09-21 Initiated Wells Fargo Overweight
Nov-19-21 Initiated BMO Capital Markets Outperform
Jul-27-21 Resumed Truist Buy
May-06-21 Downgrade Mizuho Buy → Neutral
Apr-07-21 Resumed RBC Capital Mkts Sector Perform
Feb-04-21 Upgrade DZ Bank Hold → Buy
Dec-16-20 Downgrade RBC Capital Mkts Outperform → Sector Perform
Nov-19-20 Resumed Goldman Neutral
Nov-10-20 Resumed Bernstein Mkt Perform
Oct-12-20 Downgrade Atlantic Equities Overweight → Neutral
Sep-29-20 Initiated Berenberg Hold
Jun-16-20 Initiated SVB Leerink Mkt Perform
Feb-27-20 Initiated Barclays Equal Weight
Feb-27-20 Upgrade Standpoint Research Hold → Buy
Feb-06-20 Initiated Mizuho Buy
Jan-07-20 Initiated RBC Capital Mkts Outperform
Oct-17-19 Resumed BofA/Merrill Neutral
Jul-30-19 Downgrade BofA/Merrill Buy → Neutral
Jul-30-19 Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-04-19 Resumed Morgan Stanley Overweight
Feb-20-19 Resumed Citigroup Neutral
Jan-31-19 Upgrade Argus Hold → Buy
Jan-31-19 Upgrade Credit Suisse Neutral → Outperform
Jan-23-19 Downgrade UBS Buy → Neutral
Dec-11-18 Downgrade JP Morgan Overweight → Neutral
Nov-01-18 Downgrade BMO Capital Markets Outperform → Market Perform
View All

Pfizer Inc Stock (PFE) Latest News

pulisher
03:57 AM

Pfizer (NYSE:PFE) Ends Collaboration With Acepodia And Faces Depo-Provera Legal Challenges - simplywall.st

03:57 AM
pulisher
11:30 AM

Pfizer (PFE) Down 5% Since Last Earnings Report: Can It Rebound? - Yahoo Finance

11:30 AM
pulisher
10:58 AM

Penicillin Market Research Report 2025 - GlobeNewswire Inc.

10:58 AM
pulisher
09:40 AM

Are Investors Undervaluing Pfizer (PFE) Right Now? - Nasdaq

09:40 AM
pulisher
09:38 AM

Pfizer's Mega Deal Highlights China's Rising Role In Global Pharma - Benzinga

09:38 AM
pulisher
09:04 AM

Berenberg Bank Cuts Pfizer Price Target to $25 From $28, Maintains Hold Rating - marketscreener.com

09:04 AM
pulisher
08:50 AM

5 Rock-Solid Dividend Stocks Under $50 With Room to Run - 24/7 Wall St.

08:50 AM
pulisher
08:32 AM

Old COVID tweet lands Pfizer in new trouble with PMCPA - pharmaphorum

08:32 AM
pulisher
07:07 AM

PFIZER INC : Berenberg reaffirms its Neutral rating - marketscreener.com

07:07 AM
pulisher
06:57 AM

Acute Myeloid Leukemia Market Detailed Analysis and Forecast - openPR.com

06:57 AM
pulisher
May 28, 2025

Pfizer (PFE) Stock Slides Over 2%, Hits Day’s Low in Afternoon Trading - Daily Chhattisgarh News

May 28, 2025
pulisher
May 28, 2025

With 67% ownership of the shares, Pfizer Inc. (NYSE:PFE) is heavily dominated by institutional owners - Yahoo Finance

May 28, 2025
pulisher
May 28, 2025

U.S. Vaccine Market Set to Witness Robust ExpansionPfizer, Moderna - openPR.com

May 28, 2025
pulisher
May 28, 2025

Acepodia and Pfizer To Terminate Cooperation in Autoimmune Diseases Drugs Development - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Novo Nordisk's 52% Plunge: Is the Company Fumbling Its Leadership in the $150 Billion Weight Loss Market? - The Motley Fool

May 28, 2025
pulisher
May 28, 2025

FDA Warns of Heart Risk With Pfizer, Moderna COVID Vaccines - Endocrinology Advisor

May 28, 2025
pulisher
May 27, 2025

Unlocking Pfizer's Value: Cost Controls And Oncology Pipeline - Seeking Alpha

May 27, 2025
pulisher
May 27, 2025

US drops COVID vaccine recommendation for healthy kids, pregnant women - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

Mixed options sentiment in Pfizer with shares up 0.88% - TipRanks

May 27, 2025
pulisher
May 27, 2025

US drops COVID vaccine recommendations for healthy children, pregnant women - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

Sleep Aids Market Generated Opportunities, Future Scope - openPR.com

May 27, 2025
pulisher
May 27, 2025

Is Pfizer Stock a Buy After This $1.25 Billion Investment? - The Globe and Mail

May 27, 2025
pulisher
May 27, 2025

Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance

May 27, 2025
pulisher
May 26, 2025

Enamine to Enable Access to Selected Pfizer Reference Compounds to Support the Global Research CommunityMETRO - METRO - NEWS CHANNEL NEBRASKA

May 26, 2025
pulisher
May 26, 2025

Specialty Injectable Generics Market Is Booming So Rapidly - openPR.com

May 26, 2025
pulisher
May 26, 2025

Immunostimulant Drugs Market Is Booming So Rapidly 2025-2032 - openPR.com

May 26, 2025
pulisher
May 26, 2025

Chlorphenamine Maleate API Market Trends, Demand, and Future Outlook | Pfizer Inc., Novartis AG, Sanofi S.A. - openPR.com

May 26, 2025
pulisher
May 26, 2025

Pfizer, Inc. (PFE) Stock Analysis: Evaluating a 26.50% Potential Upside Amidst Challenges - DirectorsTalk Interviews

May 26, 2025
pulisher
May 26, 2025

Investing In The Promising PD1/VEGF Bispecific; Pfizer And Instil Could Be Good Candidates - Seeking Alpha

May 26, 2025
pulisher
May 25, 2025

Pfizer (PFE) Secures $1.25B Cancer Drug Licensing Deal - GuruFocus

May 25, 2025
pulisher
May 25, 2025

25,379 Shares in Pfizer Inc. (NYSE:PFE) Bought by PVG Asset Management Corp - InsuranceNewsNet

May 25, 2025
pulisher
May 25, 2025

Pfizer’s SWOT analysis: stock outlook amid strategic moves and pipeline potential - Investing.com India

May 25, 2025
pulisher
May 24, 2025

Pfizer Inc. (PFE) Delivers Oncology Milestones with MesoC2 Debut and XTANDI Survival Boost - Yahoo Finance

May 24, 2025
pulisher
May 24, 2025

Down 63%, Should You Buy the Dip on Pfizer? - AOL.com

May 24, 2025
pulisher
May 23, 2025

Pfizer's 7.5% Dividend: Income Haven or House of Cards? - MSN

May 23, 2025
pulisher
May 23, 2025

Pfizer (NYSE:PFE) Showcases New Cancer Treatment Study And Reports Prostate Cancer Drug Success - simplywall.st

May 23, 2025
pulisher
May 23, 2025

Type 2 Diabetes Market to Expand Significantly by 2034, States DelveInsight Report | Eli Lilly and Company, Regor Pharma, AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova - The Globe and Mail

May 23, 2025
pulisher
May 23, 2025

Pfizer Inks $1.25 Billion Deal with 3SBio for Global Rights to Cancer Drug - Contract Pharma

May 23, 2025
pulisher
May 23, 2025

FDA Advisory Panel Backs COVID Vaccine Update, Impacting Pfizer (PFE) - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Nona Biosciences Collaboration Partner Pfizer Announces Presentation of Phase 1 Clinical Study Design on MesoC2, an MSLN-Targeting ADC, at the 2025 ASCO Annual Meeting - PR Newswire

May 23, 2025
pulisher
May 22, 2025

Astellas and Pfizer's XTANDI Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer - Investing News Network

May 22, 2025
pulisher
May 22, 2025

Fed. Circ. Backs Pfizer Win Against Gene Therapy Patents - Law360

May 22, 2025
pulisher
May 22, 2025

Astellas and Pfizer’s XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer - Pfizer

May 22, 2025
pulisher
May 22, 2025

Pfizer, Astellas Pharma's Prostate Cancer Treatment Shows 30% Reduction in Risk of Death - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

Astellas and Pfizer's XTANDI™ (enzalutamide) Shows Long-Term Ove - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Was Jim Cramer Right About Pfizer Inc. (PFE)? - Yahoo Finance

May 22, 2025
pulisher
May 22, 2025

Astellas and Pfizer's XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer - Yahoo Finance

May 22, 2025
pulisher
May 22, 2025

COVID shots should target newer strains of JN.1 variant, US FDA advisers say - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

Pfizer Cements Win Axing Hemophilia Patents at Federal Circuit - Bloomberg Law News

May 22, 2025
pulisher
May 22, 2025

Was Jim Cramer Right About These 12 Stocks? - Insider Monkey

May 22, 2025
pulisher
May 22, 2025

Changes are happening around COVID-19 vaccines: Here's what to know - USA Today

May 22, 2025

Pfizer Inc Stock (PFE) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$111.11
price up icon 2.46%
$283.54
price up icon 1.85%
drug_manufacturers_general GSK
$40.00
price up icon 2.09%
drug_manufacturers_general MRK
$76.40
price up icon 0.30%
drug_manufacturers_general NVO
$69.46
price up icon 1.25%
Cap:     |  Volume (24h):